French Specific Surveillance System for Drug Abuse
Authors:
- Elisabeth FraugerEFElisabeth Frauger
- Christophe MoracchiniCMChristophe Moracchini
- Françoise AlbertiniFAFrançoise Albertini
- Xavier ThirionXTXavier Thirion
- Joëlle MicallefJMJoëlle Micallef
- 3 July 2014
- journal article
- research article
- Published by Taylor & Francis in International Journal of Mental Health
- Vol. 43 (3) , 49-62
Abstract
It is important to assess drug abuse liability in real life by post-marketing surveillance system. In France, to obtain information on drug abuse liability, the Centers for Evaluation and Information on Pharmacodependence (CEIP) network was created in 1990 with the following aims: detection, prevention, evaluation, and information on drug abuse liability. Its specific work is based on a global, scientific assessment involving preclinical data, clinical studies, and post-marketing surveillance. This network has developed several pharmaco-epidemiological approaches to improve knowledge of drug use in real-life. The aim of this article was to describe a French post-marketing surveillance called OPPIDUM (Observation des Produits Psychotropes Illicites ou Détournés de leur Utilisation Médicamenteuse, Observation of Illegal Drugs and Misuse of Psychotropic Medications). OPPIDUM is an annual cross-sectional survey that collects anonymous information on abuse and dependence observed in patients recruited by specialized care centers dedicated to drug dependence. For each patient included sociodemographic data and psychoactive substance consumptions during the previous week were collected. From 1990 to 2010, a total of 50,734 patients were included with descriptions of 102,631 psychoactive substances. This OPPIDUM data has outlined emergent behaviors, such as use of high dosage buprenorphine by intravenous administration. It has contributed to characterize patients under opiate maintenance treatments and to assess abuse liability of emergent drugs as clonazepam. This pharmacoepidemiologic tool has also detected the decrease of flunitrazepam abuse following implementation of regulatory measures. OPPIDUM’s experience clearly demonstrates that collection of valid and useful data on drug abuse is possible. This post-marketing surveillance system offers important and useful information for physicians and health authorities.Keywords
This publication has 25 references indexed in Scilit:
- Monitoring of benzodiazepine diversion using a multi-indicator approachInternational Clinical Psychopharmacology, 2011
- Which psychoactive prescription drugs are illegally obtained and through which ways of acquisition? About OPPIDUM surveyFundamental & Clinical Pharmacology, 2011
- Assessment of abuse of tianeptine from a reimbursement database using ‘doctor‐shopping’ as an indicatorFundamental & Clinical Pharmacology, 2011
- Principles of laboratory assessment of drug abuse liability and implications for clinical developmentDrug and Alcohol Dependence, 2009
- Second Meeting of the French CEIP (Centres d’Évaluation et d’Information sur la Pharmacodépendance). Part I: How to Evaluate and Prevent the Abuse and Dependence on Hypnotic/Anxiolytic Drugs?Therapies, 2009
- Introduction to College on Problems of Drug Dependence special conference on risk management and post-marketing surveillance of CNS drugsDrug and Alcohol Dependence, 2009
- Premières journées nationales de pharmacodépendance (CEIP). Place de la pharmacodépendance dans l’évaluation du médicamentTherapies, 2008
- Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network surveyBritish Journal of Clinical Pharmacology, 2007
- Survey of Forged Prescriptions to Investigate Risk of Psychoactive Medications Abuse in FranceDrug Safety, 2007
- Assessment of doctor‐shopping for high dosage buprenorphine maintenance treatment in a French region: development of a new method for prescription databasePharmacoepidemiology and Drug Safety, 2003